Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

Mereo BioPharma Group plcNASDAQ: MREO

Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026

Other non-cash items turns negative

Q1 FY2026 other non-cash items was -$1.53M, compared with $2.52M a year earlier. Trailing-twelve-month other non-cash items was $2.66M.

Context

  • Other non-cash items amounted to 1179.5% of revenue in FY2025.
  • Other non-cash items increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other non-cash items holds near -$1.53M or moves back toward the trailing-twelve-month quarterly average of $665.66K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.53M+341.2% QoQ
Last fiscal yearDec 2025
$5.9M+155.3% YoY
LTMMar 2026
$2.66M-46.0% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-160.5%——
1 year+155.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
5.9M USD
Year-over-year change
+155.3%

Other Non-Cash Items vs competitors

How MREO compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -46.0% is the 5th highest of 10, against a peer median of -60.0%.
  • Other non-cash items amounts to 532.5% of revenue for MREO, versus a peer median of 55.6%.
MREO Competitors
Other Non-Cash Items for MREO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$75.39B USD+59170678.7%+171.4%—
SLNSilence Therapeutics plcLTM Mar 2026$70.22M USD——7620.1%
IMMPImmutep LimitedFY2025A$4.37M AUD+1051.6%—86.7%
PRQRProQR Therapeutics N.V.LTM Mar 2026€3.3M EUR+368.6%—24.5%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$3.22M USD-148.6%——
MREOMereo BioPharma Group plcLTM Mar 2026$2.66M USD-46.0%—532.5%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$2.45M USD-60.0%——
ACIUAC Immune S.A.LTM Dec 2025CHF 606.88K CHF-74.7%—17.0%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$562K USD+183.4%-52.2%—
CADLCandel Therapeutics, Inc.LTM Mar 2026$539K USD-91.8%-23.8%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$538.54K USD-63.0%——
Peer median (excluding MREO) —-60.0%-23.8%55.6%

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income19.22M(42.22M)(29.47M)(43.25M)(41.88M)
Depreciation & Amortization866.47K889K1.06M1.09M622K
Deferred Income Tax00000
Stock-Based Compensation4.46M4.77M4.92M7.39M7.6M
Change in Working Capital(2.49M)(2.35M)(1.59M)(369K)(3.21M)
Accounts Receivables(794.94K)(3.47M)456K(1.65M)1.4M
Inventory00000
Accounts Payables0617K(1.26M)146K(1.38M)
Other Working Capital(1.7M)498K(786K)1.13M(3.23M)
Other Non-Cash Items(29.12M)(9.91M)3.94M2.31M5.9M
Operating Cash Flow(7.07M)(48.82M)(21.13M)(32.83M)(30.97M)
Capital Expenditures(722.06K)(13K)(419K)(699K)(20K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities153.86K2M(419K)00
Investing Cash Flow(568.2K)1.99M(419K)(699K)(20K)
Debt Repayment(933.95K)0(3.19M)00
Common Stock Issued105.99M011.61M47M327.76K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(253.73K)200K24K(853K)(764)
Financing Cash Flow104.8M200K7.97M46.15M327K
Effect of Forex Changes(1.57M)(12.58M)2.82M(233K)1.93M
Net Change in Cash95.59M(59.22M)(10.76M)12.38M(28.81M)
Free Cash Flow(7.79M)(48.83M)(21.55M)(33.53M)(30.99M)

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.